Bispecific Antibody Therapeutics Market

Bispecific Antibody Therapeutics Market

Substantial rise in the number of clinical trials intended towards the development of potent and advanced bispecific drugs over the past decade has acted favorably for the global bispecific antibody therapeutics market. These trials have made these drugs a popular as well as a promising candidate for enhanced treatment of various rare medical conditions, especially a variety of cancers. At the present, there are more than 300 drug candidates in the global bispecific antibody therapeutics market. Majority of these are in their pre-clinical or clinical trial stages. Various medical technology providers and drug developers operating within the global bispecific antibody therapeutics market have started collaborating together by signing numerous licensing agreements. These efforts are undertaken to advance the development of promising pipeline drug candidates in the global bispecific antibody therapeutics market.

Researchers are focused in developing bispecific antibodies with unique pharmacological and biological properties that can prove to be promising therapeutic agents in the global bispecific antibody therapeutics market. Enhancements and innovation pertaining to the antibody and proton engineering are expected to pave way for the discovery of more potent and precise target drug candidates in the global bispecific antibody therapeutics market. Usage of these advanced bioengineering techniques has already given rise to the production capability of over 50 new drug formats in the global bispecific antibody therapeutics market in the recent past. However, limitations of these drugs, such as lack of understanding of in-vivo mechanism of drug action and increased patient resistance can hamper the global bispecific antibody therapeutics market in near future.

Bispecific Antibody Therapeutics Market: Introduction

• Bispecific antibodies are also known as artificial proteins where two or more antigen recognizing elements are attached together to form a single construct. Bispecific antibodies are capable of binding into two or more targets at a time. Moreover, these antibodies are also able to bridge two targets together and are capable to present a high chance of gaining therapeutic effects (bring cancer cell within striking distance). The different formats of bispecific antibodies are bispecific antibodies with special heterodimerization domains, quadromas, and bispecific antibodies of minimal size.
• Bispecific antibodies are primarily utilized for the treatment of cancer and are emerging as a novel technology for dual targeting strategies within one molecule for cancer treatment. Bispecific antibodies enhance and ensure following factors in a cancer targeting agent: increase binding ability, enhance selectivity, and efficacy. It has been observed that bispecific antibodies offer improved efficacy in cancer treatment as compared to that offered by the combination therapy provided by other two antibodies. Recombinant DNA technology is recognized as the backbone of faster expansion of bispecific antibody formats.

Key Drivers, Restraints, and Opportunities of Global Bispecific Antibody Therapeutics Market

• Bispecific antibodies are evolving as a most commonly used and accurate method of treatment for different cancers including lung, breast, prostate, and colon. Rise in cases of various types of cancer (breast cancer, lung cancer, and cervical cancer) the global market for Bispecific antibody therapeutics is majorly driving. According to stats by the World Health Organization (WHO) published in 2014, approximately 8.2 million people died of cancer in 2012. Likewise, the American Cancer Society (ACS) published that in 2012, around 300,000 men and 276,000 women in the U.S. died due to the cancer. Moreover, it is anticipated that most U.S. men have received a diagnosis test for prostate cancer at some point in their lives, as stated by the California Journal of Clinical Cancer (CJCC).
• However, technical complications in regard with the treatment procedure (detection) of bispecific antibodies would hamper the global Bispecific antibody therapeutics market during the forecast period. However, side-effects of bispecific antibody therapeutics and stringent regulations are anticipated to hamper the bispecific antibody therapeutics market in the next few years.

North America to Capture Major Share of Global Bispecific Antibody Therapeutics Market

The global bispecific antibody therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are anticipated to be prominent markets for bispecific antibody therapeutics, globally, as major market players are based in these regions. Moreover, the highest numbers of cancer diagnosis cases per year are estimated to have been recorded in North America and Europe. Additionally, favorable initiatives taken by the federal government further contributed to the expansion of the bispecific antibody therapeutics in North America and Europe. Similarly, Asia Pacific is considered as an untapped market in bispecific antibody therapeutics owing to a lack of proper healthcare facilities in some countries in Asia.

The market in Asia Pacific would be fuelled by the presence of untapped opportunities owing to the extensive expansion of the healthcare infrastructure (healthcare facility, healthcare cost, and health care budget). Likewise, Asia Pacific is considered to be an emerging market for bispecific antibody therapeutics owing to a rise in penetration of bispecific antibody therapeutics in the region.

Key Players Operating in Global Bispecific Antibody Therapeutics Market

The global bispecific antibody therapeutics market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major Players operating in the global bispecific antibody therapeutics market are:

• Ab Studio
• AbbVie
• AbCellera
• AbClon
• Bristol-Myers Squibb
• Calico
• Cancer Research UK
• Catalent Biologics
• Celgene
• CELLSCRIPT
• Dana-Farber Cancer Institute
• DCPrime
• Eli Lilly
• EMD Serono
• F-star
• Fuda Cancer Hospital
• FUJIFILM Diosynth Biotechnologies
• Fusion Antibodies
• FZata
• GEMoaB
• Genedata

Global Bispecific Antibody Therapeutics Market: Research Scope

Global Bispecific Antibody Therapeutics Market, by Indication

• Autoimmune disease
• oncology
• Others

Global Bispecific Antibody Therapeutics Market, by Treatment

• Enzyme blinatumomab
• Catumaxomab
• Duligotumab
• Others

Global Bispecific Antibody Therapeutics Market, by Route of Administration

• Intravenous
• Subcutaneous
• Others

Global Bispecific Antibody Therapeutics Market, by Distribution Channel

• Hospital pharmacy
• Online pharmacy
• Retail pharmacy

Global Bispecific Antibody Therapeutics Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa